Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE)
EndocrinologiaResumo original em inglês
O que aconteceu
Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status.
In this prespecified secondary analysis of the EMERGE trial, which evaluated the effectiveness of metformin vs placebo in treating GDM and found reduced gestational weight gain and longer time to insulin initiation with metformin use, we included women with a live-born infant and known infant birthweight and gestational age at delivery. We compared the numbers of SGA infants in both groups and explored baseline predictive factors to help identify those at highest risk of delivering an SGA infant.
Clinical Trials.gov NCT02980276; EudraCT number: 2016-001644-19.
O que encontraram
Baseline maternal characteristics were similar between SGA and non-SGA pregnancies. On multivariable-adjusted regression, no baseline maternal variables were associated with SGA status. Mothers of SGA infants were more likely to develop pre-eclampsia or gestational hypertension (18.2% vs 2.0%, p=0.001; 22.7% vs 5.4%, p=0.005, respectively); after multivariable adjustment, pre-eclampsia was positively associated with SGA status). Among SGA pregnancies, important perinatal outcomes including preterm birth, Caesarean delivery and neonatal care unit admission did not differ between the metformin and placebo groups (20.0% vs 14.3%, p=1.00; 50.0% vs 28.6%, p=0.25; 13.3% vs 42.9%, p=0.27, respectively).
Por que isso importa
Pre-eclampsia was strongly associated with SGA infants. Metformin-exposed SGA infants did not display a more severe SGA phenotype than infants treated with placebo.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE)
Fidelma Dunne, Christine Newman, Alberto Alvarez-Iglesias, Paula O'Shea, Declan Devane, Paddy Gillespie, Aoife Egan, Martin O'Donnell, Andrew Smyth
Descritores MeSH
- Hypoglycemic Agents
- Infant, Small for Gestational Age
- Metformin
- Diabetes, Gestational
- Gestational Age
- Humans
- Gestational Weight Gain
- Pregnancy
- Pregnancy Outcome
- Risk Factors
Veja também
Estudos relacionados
- The efficacy and safety of metformin alone or as an add-on therapy to insulin in pregnancy with GDM or T2DM: A systematic review and meta-analysis of 21 randomized controlled trials
- Metformina em Grávidas de Alto Risco Metabólico - Metaanálise de Nível de Paciente
- Metformin safety during pregnancy in women with gestational diabetes mellitus: A systematic review and meta-analysis of maternal, neonatal and long-term outcomes
- Role of Cerebroplacental Ratio in Predicting the Outcome of Pregnancies Complicated by Diabetes